Valo, Erkka
Colombo, Marco
Sandholm, Niina
McGurnaghan, Stuart J.
Blackbourn, Luke A. K.
Dunger, David B.
McKeigue, Paul M.
Forsblom, Carol
Groop, Per-Henrik
Colhoun, Helen M.
Turner, Charles
Dalton, R. Neil
Funding for this research was provided by:
Juvenile Diabetes Research Foundation International (Ref. 1-SRA-2016-333-M-R)
Folkhälsanin Tutkimussäätiö
Wilhelm och Else Stockmanns Stiftelse
Liv och Hälsa Society
Novo Nordisk Foundation (NNF OC0013659)
Helsinki University Hospital Research Funds
Academy of Finland (316664)
Finnish Diabetes Research Foundation
University of Helsinki Research Foundation
Chief Scientist Office (Ref. ETM/47)
Diabetes UK (Ref. 10/0004010)
Article History
Received: 8 December 2021
Accepted: 8 March 2022
First Online: 17 March 2022
Competing interests
: P-HG has received investigator research grants from Eli Lilly and Roche, lecture honoraria from Astellas, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Elo Water, Genzyme, MSD, Novartis, Novo Nordisk, and Sanofi. P-HG is an advisor for AbbVie, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Cebix, Eli Lilly, Janssen, MSD, Novartis, Novo Nordisk and Sanofi. HMC receives research support and honorarium and is also a member of the advisory panels and speaker’s bureaus for Sanofi Aventis, Regeneron, and Eli Lilly. HMC has been a member of DSMB of the Advisory Panel for the CANTOS Trial (Novartis Pharmaceuticals). HMC also receives or has recently received a non-binding research support from Pfizer Inc., and AstraZeneca LP. HMC is a shareholder of Roche Pharmaceuticals and Bayer. RND and CT are Directors of SpOtOn Clinical Diagnostics Ltd. EV, MC, NS, SJM, LAKB, DBD, PMM, and CF declare that there is no duality of interest associated with their contribution to this manuscript.